Intrexon | XON - Des Atouts





Des Atouts Changement Date
Agenus USD 226.8M 7.09M 2025-12
Alaunos Therapeutics USD 2.97M 758K 2025-12
Amgen USD 92.5B 1.92B 2026-03
Anika Therapeutics USD 179.39M 10.88M 2026-03
Arrowhead Research USD 1.6B 218.89M 2025-12
AstraZeneca USD 114.02B 59M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Gilead Sciences USD 59.02B 490M 2025-12
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Heron Therapeutics USD 255.88M 6.93M 2025-12
Incyte USD 7.34B 381.14M 2026-03
Intrexon USD 73.16M 77.88M 2024-06
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
Ligand Pharmaceuticals USD 1.56B 83.86M 2025-12
MacroGenics USD 256.85M 13.92M 2025-12
MannKind USD 792.18M 297.54M 2025-12
Merck USD 128.68B 8.18B 2026-03
Novartis USD 118.53B 7.58B 2026-03
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
Roche Holding CHF 100.7B 5.94B 2025-12
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Thermo Fisher Scientific USD 113.28B 2.94B 2026-03
Veracyte USD 1.41B 38.23M 2025-12
Xencor USD 875.5M 6.68M 2025-12